If its molecular form is changed, a tolerogen can become an immunogen.

Vaccination works by priming the immune system with an 'immunogen'.

An immunogen is a specific type of antigen.

Compared with the protein alone, the immunogen plus adjuvant gave an immune response that was at least 50 times higher.

The material is known as an immunogen.

Choice of immunogen remains problematic for these vectors.

An adaptive immune response is specific to the antigen that stimulated it (called the immunogen).

Therefore, by exposing an animal to an immunogen in a controlled way, its body can learn to protect itself: this is called active immunization.

Choice of immunogen is clearly problematic.

Cross-reactivity is the reaction between an antibody and an antigen that differs from the immunogen.

An immunogen is a substance that is able to provoke an adaptive immune response if injected on its own.

Immunization, or immunisation, is the process by which an individual's immune system becomes fortified against an agent (known as the immunogen).

By exposing an individual to an immunogen in a controlled way, the body will be able to protect itself from that infection later on in life.

The use of a T cell epitope-modified whole protein immunogen confers a number of advantages.

Its patent rights are owned by ImmunoGen Inc.

If the antigen does induce a response, it is an 'immunogenic antigen', which is referred to as an immunogen.

We believe, however, that to achieve a relevant alteration of the immune response will require an immunogen substantially more sophisticated than the MicroGeneSys gp160.

Generically, the process of artificial induction of immunity, in an effort to protect against infectious disease, works by 'priming' the immune system with an 'immunogen'.

Ferencik et al. describe an immunogen as a complete antigen which is composed of the macromolecular carrier and epitopes (determinants).

A sulfhydryl-containing hapten can then be reacted with the KLH to complete the immunogen without causing polymerization.

Perlmann's further research included cytotoxicity of human lymphocytes and immunogen selection and epitope mapping for malaria vaccine development.

Because the plasmid is the "vehicle" from which the immunogen is expressed, optimising vector design for maximal protein expression is essential.

This can be resolved by absorption of these antibodies with their cross-reactive antigen, leaving only the antibodies that are specific to the immunogen of interest.

This technique for the creation of an effective immunogen is most often applied to bacterial polysaccharides for the prevention of invasive bacterial disease.

Thus, every immunogen can be an antigen but not every antigen is an immunogen.